JP2022517226A5 - - Google Patents
Info
- Publication number
- JP2022517226A5 JP2022517226A5 JP2021540174A JP2021540174A JP2022517226A5 JP 2022517226 A5 JP2022517226 A5 JP 2022517226A5 JP 2021540174 A JP2021540174 A JP 2021540174A JP 2021540174 A JP2021540174 A JP 2021540174A JP 2022517226 A5 JP2022517226 A5 JP 2022517226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cd200ar
- composition
- cells
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792311P | 2019-01-14 | 2019-01-14 | |
| US62/792,311 | 2019-01-14 | ||
| PCT/US2020/013349 WO2020150149A1 (en) | 2019-01-14 | 2020-01-13 | Cd200ar ligands for cancer immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517226A JP2022517226A (ja) | 2022-03-07 |
| JP2022517226A5 true JP2022517226A5 (enExample) | 2023-01-05 |
| JP7663237B2 JP7663237B2 (ja) | 2025-04-16 |
Family
ID=69467802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540174A Active JP7663237B2 (ja) | 2019-01-14 | 2020-01-13 | がん免疫療法のためのｃｄ２００ａｒリガンド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12414983B2 (enExample) |
| EP (1) | EP3911357B1 (enExample) |
| JP (1) | JP7663237B2 (enExample) |
| AU (1) | AU2020208192A1 (enExample) |
| WO (1) | WO2020150149A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024259195A1 (en) * | 2023-06-16 | 2024-12-19 | Elias Animal Health | Use of cd200ar-l for enhancing adoptive t-cell therapy |
| WO2025259866A2 (en) * | 2024-06-14 | 2025-12-18 | Elias Animal Health | Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5744585A (en) | 1995-03-16 | 1998-04-28 | Medenica; Rajko D. | Human monoclonal antibody against lung carcinoma |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| PT1032662E (pt) | 1997-11-07 | 2006-07-31 | Trillium Therapeutics Inc | Metodos e composicoes para imunomodulacao. |
| AU2002223338B2 (en) | 2000-11-22 | 2007-06-07 | Trillium Therapeutics Inc. | Truncated CD200 |
| EP2463305B1 (en) | 2006-01-12 | 2016-05-11 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US9737598B2 (en) | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| SG10201913573UA (en) * | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| AU2016349897B2 (en) * | 2015-11-03 | 2021-11-04 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
-
2020
- 2020-01-13 JP JP2021540174A patent/JP7663237B2/ja active Active
- 2020-01-13 AU AU2020208192A patent/AU2020208192A1/en not_active Abandoned
- 2020-01-13 WO PCT/US2020/013349 patent/WO2020150149A1/en not_active Ceased
- 2020-01-13 US US17/422,641 patent/US12414983B2/en active Active
- 2020-01-13 EP EP20703675.7A patent/EP3911357B1/en active Active
-
2025
- 2025-08-22 US US19/307,588 patent/US20260158109A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dunn | Systematic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone | |
| TWI725973B (zh) | 抗-ｃｇｒｐ抗體調配物 | |
| D'Angio et al. | Potentiation of x-ray effects by actinomycin D | |
| Deng et al. | Recruitment of regulatory T cells with rCCL17 promotes M2 microglia/macrophage polarization through TGFβ/TGFβR/Smad2/3 pathway in a mouse model of intracerebral hemorrhage | |
| ES2539490T3 (es) | Métodos para proteger frente a apoptosis usando lipopéptidos | |
| WO2019170059A1 (zh) | 铁蛋白包载药物的方法及其产物 | |
| JP2021514003A5 (enExample) | ||
| RU2007134867A (ru) | Терапия рака предстательной железы ctla4-антителами и гормональной терапией | |
| Roghani et al. | Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains | |
| JP2019519584A5 (enExample) | ||
| CN101351219A (zh) | 包含增效比例的干扰素γ和α的稳定的制剂 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| FI4168033T3 (fi) | CEBP-beta -antagonistin anto ja käyttötavat | |
| JP2024537297A5 (enExample) | ||
| MX2008016059A (es) | Composiciones farmaceuticas que contienen un anticuerpo monoclonal anti-idiotipico anti-ca-125 y derivados de aluminio. | |
| CN104825402B (zh) | 一种含有吉西他滨的注射用药物组合物 | |
| CN111655275A (zh) | 用以治疗第二型糖尿病的组合物、试剂盒及方法 | |
| JP2010515670A (ja) | 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用 | |
| WO2023022872A2 (en) | Method of treating and/or preventing type 1 diabetes with cepharanthine | |
| AU2019202876B2 (en) | Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders | |
| TW202322855A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
| WO2011053700A1 (en) | Methods to mitigate injury from radiation exposure | |
| Moreira et al. | Effects of dietary creatine supplementation on kidney and striated skeletal muscles of rats submitted to ischemia and reperfusion of hind limbs | |
| A Lesnikov et al. | Neuroimmunomodulation and aging: A role for transferrin and the hypothalamus/thymus axis | |
| Arai et al. | Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice |